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Background: Aberrantly activated Notch signaling has been found in more than 50% of patients with T-cell acute
lymphoblastic leukemia (T-ALL). Current strategies that employ γ-secretase inhibitors (GSIs) to target Notch activa-
tion have not been successful. Many limitations, such as non-Notch specificity, dose-limiting gastrointestinal toxicity
and GSI resistance, have prompted an urgent need for more effective Notch signaling inhibitors for T-ALL treatment.
Human four-and-a-half LIM domain protein 1C (FHL1C) (KyoT2 in mice) has been demonstrated to suppress Notch
activation in vitro, suggesting that FHL1C may be new candidate target in T-ALL therapy. However, the role of FHL1C
in T-ALL cells remained unclear.
Methods: Using RT-PCR, we amplified full-length human FHL1C, and constructed full-length and various truncated
forms of FHL1C. Using cell transfection, flow cytometry, transmission electron microscope, real-time RT-PCR, and
Western blotting, we found that overexpression of FHL1C induced apoptosis of Jurkat cells. By using a reporter assay
and Annexin-V staining, the minimal functional sequence of FHL1C inhibiting RBP-J-mediated Notch transactivation
and inducing cell apoptosis was identified. Using real-time PCR and Western blotting, we explored the possible
molecular mechanism of FHL1C-induced apoptosis. All data were statistically analyzed with the SPSS version 12.0
software.
Results: In Jurkat cells derived from a Notch1-associated T-ALL cell line insensitive to GSI treatment, we observed
that overexpression of FHL1C, which is down-regulated in T-ALL patients, strongly induced apoptosis. Furthermore,
we verified that FHL1C-induced apoptosis depended on the RBP-J-binding motif at the C-terminus of FHL1C. Using
various truncated forms of FHL1C, we found that the RBP-J-binding motif of FHL1C had almost the same effect as
full-length FHL1C on the induction of apoptosis, suggesting that the minimal functional sequence in the RBP-J-binding
motif of FHL1C might be a new drug candidate for T-ALL treatment. We also explored the molecular mechanism of
FHL1C overexpression-induced apoptosis, which suppressed downstream target genes such as Hes1 and c-Myc and
key signaling pathways such as PI3K/AKT and NF-κB of Notch signaling involved in T-ALL progression.
Conclusions: Our study has revealed that FHL1C overexpression induces Jurkat cell apoptosis. This finding may provide
new insights in designing new Notch inhibitors based on FHL1C to treat T-ALL.
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T-cell acute lymphoblastic leukemia (T-ALL) is an aggres-
sive neoplasm that originates from immature T-cells.
Although the currently used multi-agents chemotherapy
results in 5-year relapse-free survival rates of over 75%
in children and over 50% in adults, relapse usually is
associated with resistances against chemotherapy and a
very poor prognosis [1-3]. Therefore, it is essential to
elucidate the molecular mechanisms underlying T-ALL
progression to discover new therapeutic targets for the
treatment of T-ALL.
Mutations in the Notch1 receptor have been demon-
strated as the etiological cause of T-ALL [4,5]. The first
evidence of oncogenic Notch signaling was observed in
T-ALL patients, involving translocation of a portion of
the human Notch1 gene to the TCR locus [6]. However,
this event is rare in human T-ALL (less than 1%). In fact,
more than 50% of T-ALL patients carry Notch1-activating
mutations that are usually in the heterodimerization (HD)
domain and proline/glutamic acid/serine/threonine-rich
motifs (PEST) of the Notch1 receptor, which result in
delayed degradation of Notch1 [7]. Notch1 is one of
the four mammalian Notch receptors that are single-
pass transmembrane proteins consisting of functional
extracellular, transmembrane, and intracellular domains.
When the Notch receptor is triggered upon interaction
with its ligands on neighboring cells, the Notch intracellu-
lar domain (NIC) is released from the membrane after
proteolytic cleavages executed by γ-secretase-containing
protease complexes. The NIC enters the nucleus and asso-
ciates with the DNA-binding transcription factor RBP-J
through its N-terminal RAM (RBP-J association molecule)
domain, which transactivates promoters harboring RBP-
J-binding sites by dissociating co-repressors, such as
SMRT/N-CoR, HDAC, and MINT [1,8], and recruiting
co-activators including Mastermind-like (MAML) and
p300/CBP [9]. In T-ALL, activated Notch1 regulates cell
proliferation and apoptosis by modulating the level and
activities of the related molecules/pathways such as
Hes1, c-Myc, PI3K/AKT, and NF-κB through canonical
(RBP-J-dependent) and/or non-canonical (RBP-J-inde-
pendent) signals [10,11].
Considering the critical role of Notch activation in the
progression of T-ALL, efforts have been made to cure
T-ALL by blocking Notch signaling. Small molecule
γ-secretase inhibitors (GSIs), which block the critical
proteolytic steps required for Notch activation, can be
applied for T-ALL treatment, but the clinical outcomes
have been unsatisfactory. These outcomes might be
attributed to the fact that γ-secretase is not specific for
Notch receptors, and more importantly, GSIs only affect
ligand-dependent Notch activation, not ligand-independent
Notch activation resulting from chromosome transloca-
tion or point mutations. In addition, gastrointestinaltoxicity and weak anti-leukemic effects on T-ALL also
hinder the clinical application of GSIs [12,13]. Another
target for blocking Notch signaling in malignant T cell
leukemia is RBP-J that mediates the effects of Notch1
mutants on downstream gene expression. Expression of
a dominant-negative MAML1 (DN-MAML1) in T-ALL
cell lines has been shown to antagonize Notch1 activa-
tion [14,15]. Subsequently, Moellering et al. designed a
stable α-helical peptide derived from MAML1 (SAHM1)
based on the structure of DN-MAML1. They found that
SAHM1 directly impedes assembly of the Notch1 transac-
tivation complex in the nucleus and reduces malignant
cell proliferation and promotes apoptosis. In contrast to
GSIs, DN-MAML1 and SAHM1 inhibit Notch activation
more efficiently because of their direct inhibition of Notch
signals at the transcriptional factor level. However, as a
multifunctional transcription activator, MAML1 is also
not specific for Notch signaling [16]. Thus, more effect-
ive Notch signal inhibitors are still required for the
treatment of T-ALL.
Human four-and-a-half LIM domain protein 1C (FHL1C)
(KyoT2 in mice) belongs to the four-and-a-half LIM
domain protein family and is an alternatively spliced
form of FHL1A/KyoT1. Selective use of exons results in a
frame shift in translation, generating a WW-containing
motif at the C-terminus of FHL1C, which can bind
to RBP-J. Without a transcription activation domain,
FHL1C/KyoT2 has been demonstrated to compete with
NIC for RBP-J binding and suppress RBP-J-mediated
Notch activation in vitro [8]. These findings suggest that
FHL1C may be another therapeutic target of T-ALL, but
the role of FHL1C remains to be investigated in T-ALL
cells. In the present study, we addressed this issue using
T-ALL clinical samples and the T-ALL cell line Jurkat. We
found that the expression level of FHL1C was lower in the
peripheral blood mononuclear cells (PBMCs) of T-ALL
patients than that in the controls. Overexpression of
FHL1C or its various truncates containing the RBP-J-
binding site or the minimal RBP-J-binding motif, all
resulted in Jurkat cell apoptosis. Mechanistically, FHL1C-
induced Jurkat cell apoptosis involved suppression of
downstream target genes and key pathways of Notch
signaling in T-ALL, including PI3K-AKT and NF-κB.
These findings shed light on the design of new Notch
inhibitors based on FHL1C to treat T-ALL.
Methods
Vector construction
Total RNA was extracted from a human skeletal muscle
biopsy and then reverse transcribed using a commer-
cially available kit from TAKARA (Dalian, China) with
an oligo-dT primer. This patient had signed informed
consent, and the protocol involving human samples was
approved by the Ethics Committee of Tangdu Hospital,
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accession number: AF220153.1) was amplified by PCR
with specific primers (Forward primer, 5′-ATGGCGGA
GAAGTTTGACTGCCACTACT-3′; Reverse primer, 5′-
TCACGGAGCATTTTTTGCAGTGGAAGCA-3′)
(Additional file 1: Table S1). The 585 bp PCR product
was cloned and confirmed by DNA sequencing. The
full-length FHL1C cDNA was inserted into the expres-
sion vectors pEGFP-C1 (Clontech, Mountain View, CA)
and pCMV-Myc (Clontech) to generate pEGFP-FHL1C
and pCMV-Myc-FHL1C, respectively.
To construct EGFP-tagged truncates of FHL1C, LIM1,
LIM2, and the C-terminal RBP-J-binding motif (RBPmotif )
of FHL1C, various fragments were subcloned by PCR
with the primers listed in Additional file 1: Table S1, and
pEGFP-FHL1C expression vector was used as the tem-
plate. The LIM1 and LIM2 domains were fused in frame
at the 3′ terminus to the RBPmotif to generate LIM1R
and LIM2R, respectively. LIM1R, LIM2R, and RBPmotif
were then inserted in frame into pEGFP-C1 to generate
pEGFP-LIM1R, pEGFP-LIM2R, and pEGFP-RBPmotif
(Additional file 2: Figure S3A). To construct vectors for
expression of EGFP fused to the minimal RBPmotif of
FHL1C, double-stranded oligonucleotides encoding
VWWPM, PVWWPMK, and APVWWPMKD peptides
were synthesized and cloned in frame downstream of
EGFP in pEGFP-C1. The plasmids were confirmed by
DNA sequencing.
Patients, RNA extraction, RT-PCR, Sequencing
Blood samples were collected from T-ALL patients and
normal healthy individuals (Additional file 3: Tables S3
and Additional file 4: Table S4). All patients and normal
individuals involved in the study had signed informed
consents for the use of their blood samples, except for
children under the age of 18, who had their informed
consents signed by their parents as their representatives.
The protocols involving human samples were approved
by the Ethics Committee of Tangdu Hospital, Fourth
Military Medical University. Diagnoses had been made
according to standard morphological, immunological,
and molecular genetics criteria. PBMCs were separated
by Ficoll-Hypaque density gradient centrifugation. Total
RNA was extracted from PBMCs and Jurkat cells using
Trizol reagent (Invitrogen, Carlsbad, CA), and then re-
verse transcribed using the commercially available kit
with random primers. cDNA was diluted appropriately
and used for PCR, GAPDH was used as an internal con-
trol. DNA sequences corresponding to the HD and
PEST domains were amplified using nested PCR accord-
ing to previous report [7], and then sequencing was per-
formed by Biotechnology Company.
Real-time PCR was performed as triplicate using
SYBR Premix EX Taq (TAKARA) with an ABI PRISM7300 real-time PCR system (Applied Biosystems, Life
Technologies, Carlsbad, CA) with β-actin as the refer-
ence control. Primers used for quantitative RT-PCR
are listed in Additional file 5: Table S2.
Cell culture and transfection
Jurkat cells (ATCC, Rockville, MD) were grown in RPMI
1640 supplemented with 10% fetal calf serum, 2 mM
L-glutamate, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin at 37°C in saturated humidity with 5% CO2. HeLa
and Cos7 cells (ATCC) were maintained in Dulbecco’s
modified Eagle medium (DMEM) containing the supple-
ments mentioned above.
HeLa and Cos7 cells were transfected using Lipofecta-
mine 2000 (Invitrogen) according to the recommended
protocol. Jurkat cells (1 × 106) were transfected with a
Nucleofector Kit V (Amaxa-Lonza, Cologne, Germany)
using a Nucleofector I (program X-01) following the
manufacturer’s optimized protocol.
Reporter assays
HeLa or Cos7 cells were cultured in 24-well plates and
transfected with 5 ng phRL-TK (Promega, Madison,
WI), 80 ng pGa981-6 reporter plasmid [17], 200 ng
pEF-BOS-Myc-NIC, and serial amounts (100, 300, and
500 ng) of plasmids carrying FHL1C or various truncates
of FHL1C. The cells were harvested at 48 h post-
transfection, and cell extracts were assayed for luciferase
activity using a Gloma X™ 20/20 Luminometer (Promega).
The luciferase activity was normalized to Renilla luciferase
activity.
Flow cytometric analyses of cell cycle progression and
apoptosis
Jurkat cells were resuspended in PBS and fixed in 70%
ethanol on ice for 2 h. The cells were then stained with
20 mg/ml propidium iodide (PI) in PBS containing 0.1%
Triton X-100 and 0.2 mg/ml RNase A for 30 min on ice.
The cells were analyzed by a FACSCalibur flow cyt-
ometer (BD Immunocytometry Systems, San Jose, CA).
Data were analyzed with CellQuest software.
Cell viability was routinely detected by trypan blue
exclusion. Apoptosis was determined by staining with
Annexin V-APC (eBiosciences, San Diego, CA) according
to the manufacturer’s protocol, followed by flow cytomet-
ric analysis.
Co-immunoprecipitation and western blotting
pEGFP-FHL1C and pCMV-Myc-RBP-J were transfected
into HeLa cells. Co-immunoprecipitation was performed
as described previously [17] with an anti-Myc antibody
(9E10; Santa Cruz Biotechnology, Santa Cruz, CA). Western
blotting was performed with anti-FHL1 (ProteinTech,
Wuhan, China) or anti-Myc antibodies.
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primary antibodies including anti-AKT, anti-phospho-AKT
(Signalway Antibody, Pearland, TX), anti-p50 (3354R-100;
BioVision, Mountain View, CA), or anti-β-actin (Sigma-
Aldrich, St. Louis, MO, USA). Anti-rabbit IgG and anti-
mouse IgG (Boster BioTec, Shanghai, China) were used as
secondary antibodies. Anti-c-Rel, anti-IκBα antibodies
were purchased from Eptiomics (Abcam, Burlingame,
CA). An anti-caspase 3 antibody (H-277), anti-GFP anti-
body, normal goat IgG, and normal rabbit IgG were pur-
chased from Santa Cruz Biotechnology.Fractionation of subcellular components
Jurkat cells were washed twice with PBS at 4°C and then
resuspended and incubated in buffer A (10 mM Hepes,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and a prote-
ase inhibitor cocktail) for 30 min on ice. After centrifu-
gation at 4000 rpm for 20 min at 4°C, cytosolic fractions
were collected, and the pellets were washed once in buf-
fer A, resuspended in 1% NP-40 lysis buffer (10 mM
Tris–HCl, pH 7.8, 0.5 mM EDTA, 250 mM NaCl, and
the protease inhibitor cocktail), and then incubated for
an additional 30 min on ice. After centrifugation at
10000 rpm for 15 min at 4°C, the nuclear factions were
collected. Equal amounts of each fraction were analyzed
by SDS-PAGE, followed by western blotting with the ap-
propriate antibodies.Hoechst staining
Cells were washed twice with PBS, fixed in 70% ethanol
for 20 min, and then washed again with PBS. Hoechst
diluted at 1:10,000 (final concentration: 0.12 μg/ml)
was added to cells followed by incubation in the dark
for 15 min. The cells were washed with PBS and visu-
alized under a fluorescence microscope (BX51; Olympus,
Tokyo, Japan).Figure 1 Expression of FHL1C and Hes1 was detected in T-ALL patien
in PBMCs from 8 T-ALL patients and 9 healthy donors, with GAPDH as an i
(C) to GAPDH in PBMCs from T-ALL patients and controls were compared.Transmission electron microscopy (TEM)
Sample preparation and observation under a transmis-
sion electron microscope were performed as described
previously [18].
Statistical analysis
Data were analyzed with SPSS version 12.0 software.
Results were expressed as the mean ± SD. Comparisons
between groups were performed with the unpaired Student’s
t-test. A P-value of less than 0.05 was considered statisti-
cally significant.
Results
FHL1C is down-regulated in PBMCs from T-ALL patients
FHL1C/KyoT2 has been shown to be a negative regula-
tor of the Notch pathway by competing with NIC for
binding to RBP-J in vitro. To assess the relevance of
FHL1C in T-ALL, we examined FHL1C mRNA expres-
sion in PBMCs from eight T-ALL patients and nine
healthy donors as controls by RT-PCR. We found that
FHL1C mRNA expression was significantly lower in
PBMCs from T-ALL patients compared with that in
PBMCs from healthy individuals (P < 0.05) (Figure 1A,
upper panel and B). Because Hes1 is the main down-
stream target gene of activated Notch signaling in
T-ALL [19], we also detected Hes1 mRNA expression
in T-ALL and healthy individuals. The result showed
that Hes1 mRNA expression was significantly higher in
T-ALL samples than that in healthy individuals sam-
ples (Figure 1A, lower panel and C). These results indi-
cate that FHL1C expression is down-regulated in the
PBMCs of T-ALL patients.
Overexpression of FHL1C induces apoptosis of T-ALL cells
To examine the role of FHL1C in T-ALL, we transiently
overexpressed FHL1C in Jurkat cells, a human T-ALL
cell line bearing Notch1 activation mutations. FHL1Cts and healthy donors. (A) RT-PCR analysis of FHL1C and Hes1 mRNA
nternal control. (B, C) Relative mRNA levels of FHL1C (B) and Hes1
The horizontal lines indicated median expression levels.
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into Jurkat cells by electroporation. As determined by
flow cytometric and western blotting analyses, EGFP
expression showed that highly efficient transfection was
achieved in both empty vector and pEGFP-FHL1C-
transfected Jurkat cells (Additional file 6: Figure S1A and
S1B). We monitored cell growth after transfection and
found that the number of EGFP+ Jurkat cells transfected
with pEGFP increased steadily, whereas the number of
EGFP+ Jurkat cells transfected with pEGFP-FHL1C did
not increase significantly and decreased gradually at 36 h
post-transfection (Figure 2A). This observation suggested
that overexpression of FHL1C caused cell growth arrest
and/or cell death in Jurkat cells.
We first examined the cell cycle progression of Jurkat
cells transfected with pEGFP or pEGFP-FHL1C. The
results showed no remarkable difference in the cell cycle
distribution between the two groups, although the num-
ber of cells overexpressing FHL1C exhibited a slight
increase in G2/M phase (Figure 2B and C). We next
determined cell viability after transfection. We found
that the percentage of viable cells decreased continu-
ously among Jurkat cells after transfection with pEGFP-
FHL1C, suggesting that overexpression of FHL1C might
result in cell death (Figure 2D).
Next, we directly estimated apoptosis after overexpres-
sion of FHL1C. Jurkat cells were transfected as described
above, and apoptosis was determined by flow cytometric
analysis with annexin-V and PI staining. In the GFP+
(transfected) cell population, there was a significant
increase of annexin-V+ cells among the pEGFP-FHL1C-
transfected Jurkat cells compared with that amongFigure 2 Overexpression of FHL1C in Jurkat cells resulted in reduced
pEGFP-FHL1C by using the Nucleofection method. The numbers of viable E
FACS analysis. (B, C) Cell cycle progression of Jurkat cells in (A) was determ
phase were compared between the two groups (C). (D) Total viability of Jurka
assay. Bars =means ± S.D (n = 3), *P < 0.05, **P < 0.01.the pEGFP-transfected Jurkat cells, suggesting that
overexpression of FHL1C induced apoptosis in Jurkat cells
(Figure 3A and B). Annexin-V and PI staining distin-
guishes early apoptotic (annexin V+PI−) and late apop-
totic (annexin V+PI+) cells. As Figure 3C and D were
shown, overexpression of FHL1C resulted in an in-
crease of both early and late apoptotic cells among
Jurkat cells. We also examined the morphology of Jurkat
cells transfected with pEGFP or pEGFP-FHL1C by
Hoechst staining (Figure 3E) and TEM (Figure 3F). The
results confirmed that there were more apoptotic cells
with condensed nuclei among Jurkat cells overexpress-
ing FHL1C (Figure 3E and F). At the molecular level,
overexpression of FHL1C in Jurkat cells reduced the
expression of anti-apoptosis molecules, including Bcl-2
and Bcl-x1, and increased expression of the apoptosis-
related molecule caspase 3 (Figure 3G and H). These
results strongly suggest that overexpression of FHL1C
induces apoptosis of T-ALL cells.
FHL1C induces apoptosis of Jurkat cells through
suppression of RBP-J-mediated transactivation
Similar to its murine homolog KyoT2, FHL1C also possesses
a C-terminal RBPmotif, suggesting that FHL1C interacts with
RBP-J and suppresses RBP-J-mediated transactivation.
To confirm an interaction between FHL1C and RBP-J,
we performed co-immunoprecipitation. HeLa cells were
co-transfected with expression vectors for Myc-tagged
RBP-J (pCMV-Myc-RBP-J) and EGFP-tagged FHL1C
(pEGFP-FHL1C), and immunoprecipitation was per-
formed with an anti-Myc antibody. Co-precipitated
proteins were detected using an anti-FHL1 antibody bycell viability. (A) Jurkat cells (5 × 106) were transfected with pEGFP or
GFP-positive cells were determined every 12 h by cell counting and
ined 48 h post-transfection by FACS after PI staining (B). Cells in each
t cells transfected in (A) was monitored by using trypan blue exclusion
Figure 3 FHL1C overexpression induced apoptosis in Jurkat cells. (A) Jurkat cells were transiently transfected with pEGFP or pEGFP-FHL1C
by using the Nucleofection method. Apoptosis in the GFP− and GFP+ fractions of cells was determined by AnnexinV staining followed by FACS
48 h post-transfection. (B) Percentages of apoptotic cells (Annexin V+) in GFP− and GFP+ cell fractions in (A) were compared. (C) Jurkat cells were
transfected with pEGFP or pEGFP-FHL1C by using the Nucleofection method. Early and late apoptotic cells were depicted 48 h post-transfection
by using Annexin V and PI staining followed by FACS. (D) GFP+ cells in early and late apoptotic phases in (C) were compared. (E) Jurkat cells were
transiently transfected with pEGFP or pEGFP-FHL1C by using the Nucleofection method. Cells were stained with Hoechst 24 h post-transfection
and nuclei were observed under a fluorescence microscope. Arrow heads indicate Hoechst-positive apoptotic nuclei. (F) Typical cell apoptosis in
(E) was depicted under TEM. Intact cell membrane, organelles and normal nuclear morphology were observed in vector-transfected cells, whereas
incomplete membrane and condensed nuclei were observed in cells overexpressing FHL1C (magnification, × 9900). (G) Total RNA was prepared
from cells in (E) 24 h post-transfection. The mRNA levels of the apoptosis-related molecules were determined by real time RT-PCR, with β-actin as
a reference. (H) Cell lysates were prepared from cells in (E) 24 h post-transfection. The level of Caspase3 was determined by Western blot analysis.
Bars = means ± S.D (n = 3), *P < 0.05; NS, not significant.
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Figure 4 FHL1C induced apoptosis of Jurkat cells through
repressing RBP-J. (A) Jurkat cells were transiently transfected with
pEGFP, pCMX-VP16-RBP-J, pEGFP-FHL1C or pEGFP-FHL1C plus
pCMX-VP16-RBP-J. The percentage of apoptotic (Annexin V+) cells
in EGFP+ cell population was measured 24 h after transfection.
(B) Constitutively active RBP-J blocked FHL1C-induced apoptosis
in Jurkat cells. Jurkat cells were transiently transfected with 1 μg
of pEGFP-FHL1C alone or in combination with increasing amounts (0.2,
0.5, 1.0 μg) of pCMX-VP16-RBP-J. Cell apoptosis was measured by
Annexin V staining on different days after transfection. The percentages
of apoptotic (Annexin V+) cells in EGFP+ cell population were shown.
Bars =means ± S.D (n = 3), *P < 0.05, **P < 0.01.
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FHL1C was well co-precipitated with RBP-J (Additional
file 7: Figure S2A), suggesting that FHL1C interacts
with RBP-J. Furthermore, we performed reporter assays
using HeLa and Cos7 cells by transfection with pEGFP-
FHL1C and a NIC expression vector. As a result, over-
expression of FHL1C suppressed transactivation of the
reporter harboring RBP-J-binding sites by NIC in a
dose-dependent manner (Additional file 7: Figure S2B).
This result demonstrated that FHL1C suppresses RBP-
J-mediated transactivation by competing with NIC.
We next determined whether FHL1C induced apop-
tosis of Jurkat cells through suppression of RBP-J-
mediated transactivation by overexpressing RBP-J-VP16,
a constitutively activated RBP-J [20]. Jurkat cells were
transfected with pEGFP-FHL1C alone or co-transfected
with pEGFP-FHL1C and pCMX-VP16-RBP-J, followed
by analysis of apoptosis. The results showed that Jurkat
cells did not undergo apoptosis after transfection with
pCMX-VP16-RBP-J alone, and overexpression of FHL1C
alone induced apoptosis, which was consistent with the
results shown above. Co-transfection of cells with vec-
tors carrying FHL1C and RBP-J-VP16 resulted in effi-
cient attenuation of the FHL1C-induced apoptosis
(Figure 4A). This effect was proportional to the amount
of RBP-J-VP16 (Figure 4B). These data suggest that con-
stitutively activated RBP-J protects Jurkat cells from
FHL1C-induced apoptosis, most likely through constitu-
tive activation of Notch target genes.
The C-terminal RBPmotif of FHL1C is sufficient to induce
apoptosis of Jurkat cells
FHL1C/KyoT2 is composed of two N-terminal LIM do-
mains and a 27 amino acid RBPmotif at the C-terminus
[21]. To determine which domain of FHL1C is critical
for FHL1C-induced apoptosis of Jurkat cells, various
EGFP fusion proteins in which EGFP was fused to full-
length FHL1C, LIM1R, LIM2R, or RBPmotif were trans-
fected into HeLa cells and then visualized under a
confocal fluorescence microscope. As a result, these fu-
sion proteins showed similar subcellular localization
(Additional file 2: Figure S3A and S3B). Next, we examined
the effect of these fusion proteins on RBP-J-mediated trans-
activation using a reporter assay. The results showed that
all of the fusion proteins exhibited a transcription suppres-
sion effect on RBP-J-mediated transactivation of the re-
porter gene (Additional file 2: Figure S3C), although the
full-length FHL1C fusion protein had the strongest activity.
We next evaluated the ability of these fusion proteins
to induce apoptosis of Jurkat cells. Jurkat cells were
transfected with each of the constructs, and apoptosis
was assessed at 24 h post-transfection. We found that
transfection of each construct induced apoptosis of Jurkat
cells (Figure 5A). The number of GFP+ cells decreasedcontinuously after transfection, except for EGFP-LIM1R-
overexpressing cells that showed a decrease in cell number
before 36 h post-transfection followed by an increase in
the number of GFP+ cells (Figure 5B). We next examined
the mRNA expression of critical downstream genes of
Notch signaling, which are involved in T-ALL cells includ-
ing Hes1 [19], Pten [22,23], p53 [24], and c-Myc [25,26],
and apoptosis-related genes Bcl2, BAX [27], and caspase 3
[28]. The results showed that all of the fusion proteins
down-regulated the expression of Hes1 and c-Myc, but
EGFP-LIM1R only showed a mild effect. Consistent with
the FHL1C-induced apoptosis, overexpression of these fu-
sion proteins up-regulated apoptosis-promoting molecules
while down-regulated apoptosis-inhibiting molecules
(Figure 5C). These results suggest that the RBPmotif of
FHL1C is sufficient to induce apoptosis of Jurkat cells.
Figure 5 The RBP-J-binding motif was sufficient to induce apoptosis in Jurkat cells. (A) Full length and differentially truncated FHL1C
(Additional file 7: Figure S3A) were inserted into pEGFPC1 in frame, and were used to transfect Jurkat cells. The cells were analyzed by Annexin V
staining followed by FACS 48 h post-transfection. The percentages of apoptotic (Annexin V+) cells in the EGFP+ cell population were determined.
(B) Jurkat cells were transiently transfected with plasmids as in (A). The numbers of EGFP+ cells were counted at different time points after
transfection. (C) Jurkat cells were transiently transfected with plasmids as in (A). Cells were harvested 48 h post-transfection for RNA extraction. The
mRNA expression levels of Hes1, Pten, Myc, p53, Bcl2, Bax, and Caspase3 were detected by qRT-PCR, with β-actin as a reference. (D) The core sequences with
different length of the RBP-J-binding motif in FHL1C were fused to the 3′ terminus of EGFP in frame, to construct plasmids expressing EGFP with
RBP-J-binding motif at the C-terminus. (E) EGFP containing RBP-J-binding motif inhibited NIC-mediated transactivation of RBP-J specific reporter
construct. HeLa cells were transfected with different plasmids as indicated, and luciferase activity in the cell lysates was examined 48 h after
transfection. (F) Jurkat cells were transiently transfected with plasmids as indicated. The cells were analyzed by Annexin V staining followed
by FACS 48 h after the transfection. The percentages of apoptotic (Annexin V+) cells in the EGFP+ cell population were determined. (G) Jurkat
cells were transiently transfected with plasmids as indicated. The numbers of GFP+ cells were counted at different time points after transfection.
Bars = means ± S.D (n = 3), *P < 0.05, **P < 0.01.
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peptides to disrupt Notch signaling in T-ALL cells. There-
fore, as the first step, we determined which sequence in
the RBPmotif of FHL1C could induce Jurkat cell apoptosis.
Oligonucleotides encoding various lengths of the RBPmotif
were synthesized, fused to the C-terminus of EGFP
(Figure 5D), and then overexpressed in Jurkat cells by
transfection. All constructs exhibited suppression of Notch-
mediated transcriptional activation in reporter assays, but
the construct carrying EGFP fused to the VWWPM motif
showed suppression comparable with that of full-length
FHL1C (Figure 5E). We next examined apoptosis by
annexin-V staining. In the GFP+ cell population, overex-
pression of EGFP-VWWPM efficiently induced apoptosis
of Jurkat cells, although the other two fusion proteins had
similar effects (Figure 5F). Consistently, overexpression of
EGFP fused to various lengths of the RBPmotif resulted
in a reduction of the number of transfected GFP+ Jurkat
cells (Figure 5G). These results suggest that a minimal
RBP-J-binding sequence composed of five amino acids
(VWWPM) is enough to induce apoptosis of T-ALL
cells.Figure 6 Overexpression of FHL1C induced apoptosis of Jurkat cells i
transfected with pEGFP or pEGFP-FHL1C by using the Nucleofection metho
levels of Hes1, Hes5 and c-Myc were detected by real time RT-PCR, with β-
protein level of c-Myc was determined by using Western blotting. (C,D) Ce
pEGFP-FHL1C for 48 h. AKT and phosphorylated AKT (pAKT) were analyzed
quantified and compared, with β-actin as an internal control (D). (E-G) Jurk
Nucleofection method. Cells were harvested 24 h post-transfection, and th
were determined by Western blotting (E). The relative levels of P50 (F) and
control. Bars = means ± S.D (n = 3), *P < 0.05, **P < 0.01.Overexpression of FHLIC inhibits downstream genes
and key pathways of notch signaling in T-ALL
progression
To explore whether FHL1C-mediated apoptosis of Jurkat
cells is associated with attenuation of Notch signaling,
we first examined expression of the critical downstream
genes of the Notch pathway involved in T-ALL progres-
sion using quantitative RT-PCR and western blotting. As
a result, the mRNA levels of Hes1, Hes5, and c-Myc
were significantly down-regulated by FHL1C overexpres-
sion (Figure 6A). The protein level of c-Myc was also
reduced remarkably (Figure 6B). These data indicate that
FHL1C regulates T-ALL progression by direct suppres-
sion of Notch1 target gene expression.
Furthermore, we examined the effects of FHL1C overex-
pression on the activation of PI3K/AKT and NF-κB by
western blotting, which are critical pathways activated by
Notch1 in T-ALL [29,30]. We found that overexpression of
FHL1C in Jurkat cells reduced the phosphorylation of AKT
(Figure 6C and D). Activation of NF-κB is closely associated
with Notch1-dependent T-ALL. Therefore, we examined
the levels of p50, c-Rel, and IκB in the cytosolic and nuclearnvolving multiple effectors and pathways. (A) Jurkat cells were
d. The cells were harvested 48 h post-transfection, and the mRNA
actin as a reference. (B) Jurkat cells were transfected as in (A). The
ll lysates were prepared from Jurkat cells transfected with pEGFP or
by Western blotting (C). The relative levels of AKT and pAKT were
at cells were transfected with pEGFP or pEGFP-FHL1C by using the
e cytosolic and nuclear extracts were fractioned. P50, c-Rel and IκB
c-Rel (G) were quantified and compared, with β-actin as an internal
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blotting. The results showed that the levels of p50 and
c-Rel decreased significantly in the nuclear fraction.
IκB was found primarily in the cytosolic fraction and
was also decreased slightly upon FHL1C overexpres-
sion (Figure 6E–G). This data suggest that FHL1C might
down-regulate NF-κB activity by inhibiting nuclear trans-
location of p50 and c-Rel.
Discussion
The identification of activating point mutations in Notch1
in more than 50% of T-ALL cases has spurred the devel-
opment of therapies targeting the Notch1 signaling
pathway for the treatment of T-ALL. To date, most of
these efforts have focused on inhibiting the activity of
γ-secretase, an enzyme that is essential for Notch re-
ceptor activation. Small molecule GSIs that inhibit
γ-secretase activity have been tested in clinical trials
and shown down-regulation of Notch1 target genes in
T-ALL cells [7,31]. However, GSIs are not selective for
Notch1 signaling and block other Notch receptors and
physiological pathways requiring γ-secretase. Indeed,
patients have developed marked fatigue and dose-limiting
gastrointestinal toxicity in clinical trials of GSIs, because
of the inhibition of Notch1 and Notch2 in intestinal crypt
progenitors and/or stem cells, resulting in premature
differentiation into goblet cells [32]. However, Real et al.
subsequently showed that the gut toxicity can be ame-
liorated by combinatorial therapy using GSIs and glu-
cocorticoids [12]. To avoid the side effects of GSIs,
antibodies have been developed to specifically block the
Notch1 receptor [33]. However, it has been demon-
strated that the hotspot region of Notch1 mutations in
T-ALL is the PEST domain located in the C-terminus
of Notch1, which leads to delayed NIC degradation and
thus prolonged Notch signaling. Therefore, these muta-
tions are less sensitive to anti-Notch antibodies [30,34].
In addition, some tumor cells harboring chromosomal
translocations or other genetic aberrations might not be
suitable for antibody-mediated therapy [35]. In addition to
PEST domain mutations, another region of Notch1 muta-
tions in T-ALL is the NRR region including the LNR and
HD domains, in which mutations lead to ligand hypersen-
sitivity and ligand-independent activation [7]. Although
anti-NRR antibodies have been developed, sustained treat-
ment with these antibodies will likely cause vascular
neoplasms [36]. More recently, Roti et al. demonstrated
that inhibition of SERCA (sacro/endoplasmic reticulum
Ca2+-ATPase) calcium pumps preferentially affects the
maturation and activity of mutant Notch1 receptors,
leading to enhanced clearance of the mutant Notch pro-
tein. Even if SERCA can be specifically targeted, such
inhibition does not effect on T-ALL cells with activated
Myc mutations or lacking NRR region [37].The transactivation complex NIC-RBP-J-MAML1 is
critical for signaling from Notch receptors, and is thus
becoming a promising therapeutic target for T-ALL at the
transcription level. Recently, Moellering et al. showed that
SAHM1 suppresses the transcriptional complexes of
Notch signaling. Treatment of leukemic cells with SAHM1
inhibits cell proliferation in vitro and in a Notch1-
driven T-ALL mouse model without prominent gut
toxicity [16]. In the current study, we found that over-
expression of FHL1C induced apoptosis of the Jurkat
T-ALL cell line in vitro. FHL1C overexpression down-
regulated c-Myc expression and attenuated the PI3K/
AKT pathway and NF-κB signaling. These mechanisms
may be involved in the enhanced apoptosis of Jurkat cells
overexpressing FHL1C (Additional file 8: Figure S4),
and suggest that FHL1C may be another therapeutic
target for T-ALL at the transcriptional level. Moreover,
it has been shown that Pten plays an important role in
negative regulation of PI3K/AKT signaling in T-ALL.
However, because Jurkat cells lack active Pten protein
expression, it is possible that FHL1C can suppress AKT by
other mechanisms such as disruption of the NICD-P56Lck-
PI3K complex [30,38,39]. Further studies are needed to
investigate whether FHL1C can inhibit AKT activation
through Pten in native T-ALL cells.
FHL1 is a member of the FHL protein family that
contains four-and-a-half LIM domains. FHL1 family
members interact with many proteins through their LIM
domains, including transcription factors, enzymes, and
cytoskeleton proteins. These proteins play important
roles in cell differentiation and cytoskeleton formation.
Recent studies have shown that FHL1 also has important
functions in tumorigenesis and cancer progression. FHL1
expression is suppressed in a variety of tumors including
lung cancer, breast cancer, brain tumors, and gastric
cancer [40,41]. In contrast, some reports show that
FHL1 is expressed at a high level in a squamous cell
carcinoma cell line [42]. FHL1 is aberrantly expressed in
most T-ALL cell lines, particularly those exhibiting deregu-
lated TLX1/HOX11 expression after specific chromosome
translocation [43]. In our study using PBMCs from
T-ALL patients, we detected FHL1A expression in two
cases, but the significance and underlying mechanism are
unclear. We also detected significant down-regulation of
FHL1C expression in PBMCs of T-ALL patient, accom-
panied by up-regulation of Hes1, a Notch target gene
involved in T-ALL progression. These results suggest that
FHL1C may be involved in T-ALL progression and can be
used as a therapeutic target of the disease. However, the
mechanism regulating FHL1C expression in T-ALL cells
remains unknown, and whether FHL1C is involved in
other cancers is unclear. In addition, although FHL1B
(KyoT3) is another isoform of FHL1, which encodes a
34 kDa polypeptide containing the same RBPmotif found in
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T-ALL patients or normal healthy individuals.
FHL1C/KyoT2 encodes a 22 kDa protein sharing the
two N-terminal LIM domains with FHL1A, and a 27
amino acid RBP-J-binding region at the C-terminus
generated by alternative splicing. FHL1C/KyoT2 may
participate in suppression of RBP-J-mediated Notch
signaling by two mechanisms: competing with NIC for
binding to RBP-J [17,46] or recruitment of co-repressors.
The LIM domain is a protein interaction interface that is
involved in linking proteins with the actin cytoskeleton
and/or transcriptional machinery [47,48]. Our previous
studies have shown that KyoT2 might suppress RBP-J-
mediated Notch transactivation by recruiting the Poly-
comb suppression complex including RING1 and HPC2
through the LIM domains. Furthermore, KyoT2-mediated
repression of Notch transactivation may be regulated by
sumoylation involving PIAS1 [17,46,49]. In this study, we
showed that overexpression of FHL1C induced apoptosis
of Jurkat cells. Through a series of structure-function ana-
lyses, we found that such apoptosis was mainly mediated
through the C-terminal RBPmotif of FHL1C, suggesting
that competitive binding to RBP-J might be the major
mechanism. Nevertheless, we cannot exclude the involve-
ment of other interacting molecules. More importantly,
we found that a minimal pentapeptide motif, VWWPM,
suppressed RBP-J-mediated Notch activation and induced
apoptosis of T-ALL cells at a relatively high efficiency. We
expect that this peptide sequence will benefit future
Notch-targeted therapies of T-ALL.
Conclusions
Taken together, our study revealed that overexpression
of FHL1C induces Jurkat cell apoptosis. This finding
may provide new insights into the design of new Notch
inhibitors based on FHL1C to treat T-ALL in the future.
Additional files
Additional file 1: Table S1. The sequences of PCR primers used in the
study.
Additional file 2: Figure S3. Construction of different truncates of
FHL1C containing the RBP-J-binding motif. (A) Schematic diagrams of
constructs expressing EGFP fused with different truncated FHL1C. (B)
Locations of these different truncates of FHL1C in HeLa cells. HeLa cells
were transiently transfected with the indicated plasmids. The cells were
stained with Hoechst 24 h post-transfection, and examined under a
confocal microscope. Scale bars = 20 μm. (C) Full length and different
truncated FHL1C were inserted into pEGFPC1 in frame, and were used to
transfect HeLa cells with NIC-expressing vector and pGa981-6 (the reporter
plasmid). Cells were harvested 48 h post-transfection, and luciferase activity
in cell lysates was analyzed.
Additional file 3: Table S3. Clinical characteristics of patients suffering
from T-ALL.
Additional file 4: Table S4. Clinical characteristics of healthy donors.
Additional file 5: Table S2. The sequences of real time PCR primers.Additional file 6: Figure S1. Overexpression of EGFP-FHL1C fusion
protein in Jurkat cells. (A) Jurkat cells (5 × 106) were transfected with
pEGFP or pEGFP-FHL1C by using the Nucleofection method. Cells were
observed under a fluorescence microscope (upper) and analyzed by FACS
(lower) 48 h post-transfection, the expression of EGFP or EGFP-FHL1C was
determined by FACS respectively. (B) Cell lysates were prepared from
Jurkat cells in (A), and the expression of EGFP or EGFP-FHL1C was
determined by Western blotting using anti-EGFP antibody, with β-actin as
an internal control.
Additional file 7: Figure S2. FHL1C interacted with RBP-J and inhibited
Notch signaling. (A) HeLa cells were transfected with pEGFP-FHL1C and
pCMV-Myc-RBP-J as indicated. Cell lysates were prepared 48 h post-transfection,
and the interaction between FHL1C and RBP-J was determined by
using co-immunoprecipitation. (B) HeLa and Cos7 cells were transfected
with plasmids as indicated, and luciferase activities in cell lysates were
examined 48 h post-transfection.
Additional file 8: Figure S4. Potential molecular mechanism of
FHL1C-mediated regulation of T-ALL progression. FHL1C represses
Notch1-dependent T-ALL progression by suppressing critical downstream
molecules and pathways of Notch signaling through RBP-J. Solid lines show
tested signaling pathway. Dotted lines show untested signaling pathway.
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